Steven Dow

Steven W. Dow
Professor

Phone: 491-6146
Fax: 491-0603
Email: Steven.Dow@colostate.edu
Office: 327 Pathology Building
Lab: 304 Pathology / Infectious Disease Annex, Foothills Campus

Degrees

BA, University of Virginia
DVM, University of Georgia
PhD, Colorado State University, Dept of Pathology

Current Laboratory Staff

Research Scientists: Amanda Guth, Tracy Lehman
Post-doctoral fellows: Leah Mitchell, Ediane Silva
Graduate students: Andrew Goodyear, Angie Duffy, Kara Mosovsky
Post-DVM Fellows: Jessica Quimby, Kelly Walton, Valerie Johnson, Shannon McLeland
PVM Students: Lauren Habenicht, Mike Deogracias
Undergraduate Students: Laura Steele

Research Interests and Current Projects

Lab website: http://www.cvmbs.colostate.edu/mip/dowlab/

Our laboratory studies the role of innate immunity in the development and progression of cancer and in the pathogenesis of bacterial infections, including the agents Burkholderia, Yersinia and Francisella. In addition, the laboratory is investigating the use of novel immunotherapeutics to treat or prevent bacterial and viral infections and cancer and in the development of new vaccine adjuvants.

Current projects in the laboratory include:

Role of innate immunity in the pathogenesis of pneumonic Burkholderia infection

Development of an orally-administered vaccine for pneumonic plague

Use of TLR-based immunotherapeutics for prevention of Francisella and Burkholderia infections.

Use of TLR-based immunotherapeutics for treatment of local and metastatic cancer

Role of interferons and macrophages in regulation of tumor growth

Role of bone infection in prevention of tumor metastasis

Selected Early and Recent Publications

Pub Med for Dow S.

Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, and Potter TA. (1998) In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101, 2406-2414.

Dow SW, Dubard CM, and Hoover EA. (1999) In vivo monocyte tropism or pathogenic feline immunodeficiency viruses. J Virol 73:6852-6861.

Dow SW, Liggitt DL, Fradkin L, and Potter TA. (1999)Potent immune activation and antitumor immunity induced by intravenous administration of cationic lipid-DNA complexes. J Immunol 163:1552-1561.

Kedl R, Jordan M, Kappler J, Potter T, Marrack P, and Dow S (2001)CD40 stimulation accelerates depletion of tumor-specific CD8+ T cells in the absence of tumor antigen vaccination. Proc Natl Acad Sci 98:10811-10816.

Bosio C, Goodyear A, and Dow S(2005) Early interaction of Yersinia pestis with APCs in the lungs. J Immunol 175:6750-6756.

Bosio C and Dow S(2005) Aberrant activation of pulmonary dendritic cells by Francisella tularensis. J Immunol 175:6792-6801.

Kamstock D, Guth A, Elmslie R, Kurzman I, Fairman J, Coro L, and Dow S (2006) Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 13, 306-317.

Gowen B, Fairman J, Smee D, Wong M, Jung K, Pace A, Heiner M, Bailey K, Dow S, and Sidwell R.(2006)Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Research 69:165-172.

U’Ren L, Kedl R, and Dow S.(2006) Immunization with liposome-DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther, 13:1033-

Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, and Dow S.(2006)Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 and TLR9 agonists complexed to cationic liposomes.J Immunol, 176:7335-7345.

Dow S.Liposome-nucleic acid immunotherapeutics.(2008) Expert Opinion in Drug Delivery 5:11-24.

Elmslie R, Glawe P, and Dow S.(2008) Metronomic chemotherapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcoma, J Vet Intern Med, 22:1373-1379.

Guth A, Bosio C, Janssen W, Crouch E, Henson P, and Dow S.(2009) Lung environment determines unique phenotype of alveolar macrophages.J. Physiol Lung Cell Mol Biol; 296:L936-946.

Goodyear A, Troyer R, Jones A, and Dow S.(2009) Protection from Burkholderia infection by inhalational immunotherapy.Infection and Immunity 77:1759-1765.

Troyer R, Propst K, Fairman, J, Bosio K, and Dow S. (2009) Mucosal immunotherapy for protection from pneumonic Francisella infection.Vaccine 27:4424-4433.

Sottnik J, Guth A, Thamm D, and Dow S. (2009) Chronic bacterial infection suppresses tumor growth via NK cell and macrophage mediated immunity. Cancer Immunol Immunother, in press.

O’Neill K, Guth A, Biller B, and Dow S. (2009) Regulatory T cells responses and tumor associations in dogs with cancer. J Vet Intern Med:23, 875-881.

Takeda T, Dow S, Miyahara N, Kodama T, Koya T, Taube C, Joetham A, Park J, Dakhama A, Kedl R, and Gelfand E.(2009) Vaccine-induced CD8+ T cell suppression of airway hyperresponsiveness and inflammation.J Immunol, 183:181-190.

Hafeman S, Guth A, and Dow S. (2009) Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunoth, in press.

Goodyear A, Troyer R, Jones A, and Dow S.Critical role for MCP-1 in resistance to pneumonic Burkholderia infection.J Immunol, under revision, 2009.